Literature DB >> 24659095

[Rituximab for treatment of Felty’s syndrome].

H Becker, H Appel, T Fassbinder, D Heitzmann, P Willeke, A M Jacobi.   

Abstract

Felty’s syndrome is a rare variant of severe seropositive rheumatoid arthritis with neutropenia and splenomegaly. It is difficult to treat and associated with a poor prognosis due to the substantial risk of infections. This article presents the case of a patient with refractory disease who responded to rituximab with permanent normalization of neutrophil counts. Repeated infusions were necessary to induce and maintain remission.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24659095     DOI: 10.1007/s00393-014-1380-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  10 in total

Review 1.  Etanercept in treatment of Felty's syndrome.

Authors:  A Ghavami; S Genevay; T Fulpius; C Gabay
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

2.  Lack of efficacy of rituximab in Felty's syndrome.

Authors:  C Sordet; J-E Gottenberg; B Hellmich; P Kieffer; X Mariette; J Sibilia
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

3.  Neutropenia in Felty's syndrome successfully treated with hydroxychloroquine.

Authors:  Matthieu Mahévas; Sylvain Audia; Victoire De Lastours; Marc Michel; Bernard Bonotte; Bertrand Godeau
Journal:  Haematologica       Date:  2007-07       Impact factor: 9.941

4.  Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome.

Authors:  A Salama; U Schneider; T Dörner
Journal:  Ann Rheum Dis       Date:  2008-06       Impact factor: 19.103

Review 5.  Biological agents in the management of Felty's syndrome: a systematic review.

Authors:  Javier Narváez; Eva Domingo-Domenech; Carmen Gómez-Vaquero; Laura López-Vives; Paula Estrada; María Aparicio; Irene Martín-Esteve; Joan Miquel Nolla
Journal:  Semin Arthritis Rheum       Date:  2011-11-25       Impact factor: 5.532

6.  Methotrexate treatment in Felty's syndrome.

Authors:  S Wassenberg; G Herborn; R Rau
Journal:  Br J Rheumatol       Date:  1998-08

Review 7.  The spectrum of large granular lymphocyte leukemia and Felty's syndrome.

Authors:  Xin Liu; Thomas P Loughran
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

8.  Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).

Authors:  Andrea Rubbert-Roth; Paul P Tak; Cristiano Zerbini; Jean-Luc Tremblay; Luis Carreño; Gillian Armstrong; Neil Collinson; Tim M Shaw
Journal:  Rheumatology (Oxford)       Date:  2010-05-12       Impact factor: 7.580

Review 9.  Felty's syndrome.

Authors:  Geza P Balint; Peter V Balint
Journal:  Best Pract Res Clin Rheumatol       Date:  2004-10       Impact factor: 4.098

10.  Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus.

Authors:  Bernhard Hellmich; Elena Csernok; Helmut Schatz; Wolfgang L Gross; Armin Schnabel
Journal:  Arthritis Rheum       Date:  2002-09
  10 in total
  1 in total

Review 1.  Porto-Sinusoidal Vascular Disease as the Cause of Portal Hypertension in Felty's Syndrome: A Case Report and Literature Review.

Authors:  Song Yang; Min Quan; Yue Li; Calvin Qian Pan; Huichun Xing
Journal:  Biomed Res Int       Date:  2020-07-01       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.